IMP2' Antibody

What is IMP2/p62 and what are its primary functions?

IMP2/p62 (IGF2BP2) is an RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This protein functions in mRNA transport and transient storage through transcript "caging" into mRNPs. It also modulates the rate and location at which target transcripts encounter translational machinery and protects them from endonuclease attacks or microRNA-mediated degradation. IMP2 preferentially binds to N6-methyladenosine (m6A)-containing mRNAs, enhancing their stability through specific binding mechanisms .

Which cellular processes are influenced by IMP2?

IMP2 influences multiple cellular processes, including cell migration, cell adhesion, and post-transcriptional gene regulation. Research has demonstrated that overexpression of p62/IMP2 in breast cancer cells increases cell migration by 50-70% in wound healing assays and reduces cell adhesion to collagen and fibronectin by 30-50%. Interestingly, p62/IMP2 expression does not appear to impact cell proliferation rates over a 6-7 day monitoring period . The protein also regulates mRNA stability of specific targets including CTGF (Connective Tissue Growth Factor), where it can extend mRNA half-life from 2.2 hours to 5.1 hours in breast cancer cell models .

How is IMP2 expression altered in cancerous tissues?

IMP2 exhibits significantly higher expression in breast cancer tissues compared to normal tissues. Immunohistochemical (IHC) analysis reveals overexpression of p62/IMP2 in 72 out of 104 cases of human breast cancer . This pattern of overexpression appears to be consistent with observations in other cancers, including hepatocellular carcinoma and colorectal cancer. Liu et al. identified overexpression of p62/IMP2 in colon cancer tissues via IHC analyses, suggesting a common pattern of dysregulation across different cancer types .

What are the typical applications for IMP2 antibodies in research?

IMP2 antibodies are routinely used in multiple research applications including:

• Western blotting (WB) for protein expression analysis

• Immunoprecipitation (IP) for protein-protein or protein-RNA interaction studies

• Immunohistochemistry (IHC-P) for tissue localization studies

• RNA immunoprecipitation for studying RNA-protein interactions

Both monoclonal and polyclonal antibodies for IMP2/IGF2BP2 are available, with validation for human and mouse samples being most common .

How do experimental conditions affect RNA-protein immunoprecipitation efficiency with IMP2 antibodies?

When performing RNA immunoprecipitation (RIP) with IMP2 antibodies, several factors critically influence experimental success. Cross-linking conditions must be optimized based on the specific protein-RNA interaction characteristics of IMP2. Research has shown that p62/IMP2 binds target mRNAs at the 5' or 3' untranslated regions (UTRs), requiring careful consideration of cross-linking protocols .

For optimal results, researchers should:

• Validate antibody specificity using appropriate controls (GAPDH has been used as a negative control in IMP2 RIP experiments)

• Optimize cross-linking time based on the specific cell type

• Consider using formaldehyde or UV cross-linking depending on the binding characteristics

• Include RNase inhibitors throughout the immunoprecipitation procedure

• Validate results using complementary approaches such as EMSA (Electrophoretic Mobility Shift Assay)

Studies have successfully demonstrated IMP2 binding to CTGF mRNA using RIP methodology with appropriate controls, validating the technical approach .

What methodological considerations are important when evaluating IMP2 autoantibody responses in patient samples?

Detection of autoantibody responses to p62/IMP2 in patient sera requires careful methodological consideration. Multiple techniques have been validated for this purpose, with ELISA being the most widely employed. For reliable results, researchers should:

• Use recombinant p62/IMP2 protein as the coating antigen in ELISA assays

• Establish appropriate cutoff values based on normal control populations

• Confirm positive results with orthogonal methods such as Western blotting and indirect immunofluorescence assays

• Include appropriate positive and negative controls in each experiment

Studies have shown significant differences in autoantibody prevalence between cancer patients and controls. For example, the positive frequency of detectable p62/IMP2 autoantibody was 29% (63/216) in breast cancer patients, compared to only 1% (1/73) in normal individuals and 0% (0/34) in patients with benign breast lumps . Another study reported a 14.3% (7/49) frequency in breast cancer patients versus 2.2% (1/44) in normal individuals .

How can researchers distinguish between IMP2 and other members of the IGF2BP family in experimental settings?

The IGF2BP family consists of three members (IGF2BP1-3) with structural and functional similarities that can complicate specific detection. To ensure IMP2/IGF2BP2 specificity:

• Select antibodies raised against unique epitopes within the IMP2 sequence. Antibodies targeting regions within amino acids 500-599 of human IGF2BP2 have demonstrated good specificity

• Validate antibody specificity using overexpression and knockdown approaches

• Employ negative controls including other IGF2BP family members in parallel experiments

• Consider using monoclonal antibodies when absolute specificity is required

• Perform rigorous validation using multiple techniques (Western blot, immunoprecipitation, immunofluorescence)

Research findings demonstrate that even within highly conserved protein families, careful antibody selection can achieve specific target recognition, enabling accurate characterization of IMP2-specific functions distinct from other family members .

What is the relationship between IMP2 expression and mRNA stability of target transcripts?

IMP2 significantly enhances the stability of its target mRNAs through direct binding interactions. Experimental approaches to study this relationship include:

• Actinomycin D chase experiments to determine mRNA half-life in IMP2-expressing versus control cells

• Site-directed mutagenesis of predicted IMP2 binding sites to validate direct interaction

• Comparison of total versus polysome-associated mRNA levels to distinguish effects on stability versus translation

Experimental evidence demonstrates that IMP2 binding can dramatically increase target mRNA stability. In breast cancer cells, IMP2 binding to CTGF mRNA increases its half-life from 2.2 ± 0.03 hours to 5.1 ± 0.02 hours, representing a 2.3-fold increase . This stabilization mechanism appears to be mediated through IMP2 binding to specific regions within the mRNA, potentially protecting these regions from degradation machinery.

What validation steps are essential when using a new IMP2 antibody for research applications?

Before employing a new IMP2 antibody in critical experiments, comprehensive validation is essential:

• Specificity validation:

  • Western blot analysis using positive control samples (cell lines with known IMP2 expression)

  • Signal abolishment following IMP2 knockdown or knockout

  • Absence of cross-reactivity with other IGF2BP family members

  • Peptide competition assays to confirm epitope specificity

• Application-specific validation:

  • For IHC: Optimization of antigen retrieval, antibody concentration, and incubation conditions

  • For IP: Verification of pull-down efficiency and specificity

  • For IF: Confirmation of expected subcellular localization pattern

• Cross-species reactivity assessment:

  • Testing on samples from different species if cross-reactivity is claimed

  • Sequence alignment analysis to predict potential cross-reactivity

Commercial IMP2 antibodies have been validated for specific applications, with some showing reactivity to human, mouse, and rat samples .

How should researchers design experiments to assess the functional consequences of IMP2 dysregulation?

Designing robust experiments to investigate IMP2 function requires multifaceted approaches:

• Expression modulation strategies:

  • Stable transfection with p62/IMP2 expression vectors (as demonstrated in MDA-MB-231 and LM2-4 cell lines)

  • siRNA or shRNA-medicated knockdown to reduce expression

  • CRISPR-Cas9 genome editing for complete knockout

• Functional assays:

  • Migration assays: Wound healing assays have demonstrated 50-70% increased migration in IMP2-overexpressing cells

  • Adhesion assays: Testing attachment to ECM components like collagen and fibronectin has shown 30-50% reduced adhesion in IMP2-positive cells

  • Proliferation monitoring: Although no significant effects were observed in breast cancer models, this should be assessed in each experimental system

• Molecular mechanism investigations:

  • RNA immunoprecipitation to identify bound mRNA targets

  • Actinomycin D chase experiments to assess mRNA stability effects

  • Polysome profiling to evaluate translation efficiency impacts

These methodological approaches provide complementary data sets that collectively establish the functional consequences of IMP2 dysregulation in specific experimental systems.

What controls are necessary when evaluating IMP2 autoantibody presence in clinical samples?

To ensure reliable detection of IMP2 autoantibodies in clinical samples:

• Essential controls:

  • Positive control: Confirmed positive patient samples

  • Negative controls: Healthy donor samples

  • Technical negative controls: Wells without primary antibody

  • Specificity controls: Pre-absorption with recombinant IMP2 protein

• Statistical considerations:

  • Establish cutoff values based on mean plus 2-3 standard deviations of control population values

  • Include sufficient numbers of control samples (studies have used 44-73 normal controls)

  • Age and gender-matching between patient and control groups where possible

• Clinical sample collection standardization:

  • Consistent sample processing protocols

  • Standardized storage conditions

  • Detailed clinical annotation of samples

Research has demonstrated significant differences in positivity rates between cancer patients (14.3-29%) and normal individuals (1-2.2%), highlighting the importance of proper controls and cutoff determination .

How can researchers address inconsistent IMP2 antibody staining patterns in immunohistochemistry?

Inconsistent IHC staining with IMP2 antibodies may result from several factors:

• Technical optimization parameters:

  • Antigen retrieval method: Test both heat-induced (citrate or EDTA buffer) and enzymatic methods

  • Antibody concentration: Perform titration experiments to determine optimal dilution

  • Incubation conditions: Optimize temperature (4°C vs. room temperature) and duration

  • Detection system: Compare sensitivity of different visualization methods

• Sample preparation considerations:

  • Fixation protocol: Overfixation can mask epitopes

  • Tissue processing: Consistent sectioning thickness

  • Storage conditions: Minimize time between sectioning and staining

• Controls for interpretation:

  • Include known positive tissues in each staining run

  • Use isotype-matched control antibodies

  • Compare monoclonal and polyclonal antibodies if available

Studies evaluating IMP2 expression in breast cancer tissues have successfully employed IHC techniques, revealing significant overexpression compared to normal tissues .

What factors might influence detection of IMP2-mRNA interactions in RNA immunoprecipitation experiments?

RNA immunoprecipitation (RIP) experiments investigating IMP2-RNA interactions require careful consideration of:

• Cross-linking efficiency factors:

  • Cell type and density

  • Cross-linking agent selection (formaldehyde vs. UV)

  • Cross-linking duration and conditions

• Antibody selection considerations:

  • Epitope location relative to RNA-binding domains

  • Antibody affinity and specificity

  • Required antibody concentration

• RNase contamination prevention:

  • Use of RNase inhibitors throughout the protocol

  • RNase-free reagents and consumables

  • Careful temperature control during processing

• RNA quality assessment:

  • RNA integrity analysis prior to downstream applications

  • Appropriate normalization strategies

  • Comparison to input controls

Research has successfully demonstrated IMP2 binding to CTGF mRNA using RIP approaches, confirming that with proper controls and optimization, these interactions can be reliably detected .

How should conflicting data regarding IMP2 function in different experimental systems be reconciled?

When encountering contradictory results regarding IMP2 function across different studies:

• System-specific factors to evaluate:

  • Cell type and tissue origin differences

  • Expression level variations across experimental models

  • Genetic background considerations

  • Microenvironment influences

• Methodological comparison:

  • Antibody sources and validation methods

  • Detection techniques and sensitivity limitations

  • Data normalization approaches

  • Statistical analysis methods

• Reconciliation strategies:

  • Direct side-by-side comparison using standardized protocols

  • Meta-analysis of published data

  • Consideration of context-dependent functions

  • Investigation of potential interacting partners that may differ between systems

IMP2 has been shown to promote migration in breast cancer cells, while its effects on proliferation were not significant in the same model system, highlighting the importance of evaluating multiple functional endpoints .

What emerging technologies might enhance the study of IMP2-RNA interactions in living cells?

Advanced technologies offer new opportunities to investigate IMP2-RNA dynamics:

• Live-cell imaging approaches:

  • MS2-GFP system for RNA visualization combined with fluorescently tagged IMP2

  • FRAP (Fluorescence Recovery After Photobleaching) to study binding kinetics

  • Single-molecule tracking to analyze IMP2-RNA complex mobility

• Proximity-based labeling methods:

  • APEX2-mediated proximity labeling of the IMP2 RNA interactome

  • RNA-protein interaction detection using TRIBE (Targets of RNA-binding proteins Identified By Editing)

  • Biotinylation-based approaches for capturing transient interactions

• High-throughput screening applications:

  • CRISPR screens to identify factors influencing IMP2-RNA interactions

  • Small molecule library screening to identify modulators of IMP2 function

  • RNA aptamer selections to develop tools for IMP2 detection and manipulation

These emerging methodologies will allow researchers to move beyond static analyses to understand the dynamic nature of IMP2's interactions with target RNAs in physiologically relevant contexts.

How might IMP2 antibodies be utilized in translational research applications?

IMP2 antibodies have significant potential in translational research contexts:

• Diagnostic applications:

  • Tissue-based detection of IMP2 overexpression as a potential biomarker

  • Serum autoantibody detection as a non-invasive screening approach

  • Development of multiplexed panels incorporating IMP2 status

• Therapeutic target evaluation:

  • Target engagement studies in preclinical models

  • Pharmacodynamic marker development

  • Patient stratification based on IMP2 expression profiles

• Response prediction applications:

  • Correlation of IMP2 status with treatment outcomes

  • Identification of synthetic lethal interactions with IMP2 overexpression

  • Monitoring of treatment-induced changes in IMP2 expression or localization

The presence of autoantibodies to IMP2/p62 in 29% of breast cancer patients compared to only 1% of normal individuals suggests potential utility as a biomarker . Additionally, antibodies can be valuable tools in validating IMP2 as a therapeutic target in cancer and metabolic disorders .